Ekam Imaging

Ekam Imaging with partners is hosting imaging symposium on 22 September, 2011 at Northeastern University Campus:

August 02, 2011

 

Biotrofix and Ekam Imaging Release: Strategic Alliance between Research Firms Will Combine Expertise in CNS and Vascular Disease Models with Translational, Multi-Modal Imaging 

February 02, 2011

Boston, MA — Aiming to minimize risk from preclinical development, Biotrofix and Ekam Imaging announced this month they have entered into a partnering agreement together to provide synergistic capabilities to the pharmaceutical and biotechnology industries. The goal of the partnership is to deliver high-quality, accurate and translatable data that greatly assists their sponsors by allowing them to make faster and better- informed decisions. .......

 

Ekam Imaging Inc. Announces Commercialization of Imaging Technology to Support Drug Discovery and Development for Central Nervous System Diseases 

March 11, 2010

(Shrewsbury and Boston, MA) -- In a significant breakthrough in assisting early-stage drug development, especially for Central Nervous System (CNS) diseases and conditions such as Alzheimer’s and Parkinson’s Disease, Schizophrenia and Post Traumatic Stress Disorder (PTSD), Ekam Imaging Inc. is pleased to announce a new service offering positioned to transform the way in which new therapies are discovered and developed. Ekam is the only Contract Research Organization (CRO) now capable of performing translatable, multi-modal imaging studies (fMRI and molecular) using awake, unanesthetized animals. This unique and proprietary capability provides the critical tools for evaluating, in real time, the progression of disease and the efficacy and safety of novel therapeutics designed to treat many of the unmet medical needs affecting so many patients throughout the world...........

 

Awake Animal Imaging and Analysis
Mark Nedelman, President, Ekam Imaging Inc., Shrewsbury and Boston, Mass.
Drug Discovery & Development

March 01, 2010

A major limitation of current non-clinical imaging—especially relating to the brain—is that animals must be anesthetized.1 This creates a significant gap in the ability to provide serial data in diseases affecting the brain and for new and existing drugs focused on the central nervous system (CNS). With the advent of functional magnetic resonance imaging (fMRI) in awake animals, it is now possible to resolve changes in or patterns of neuronal activity across the entire brain with exquisite spatial and temporal resolution by evaluating a change in blood oxygen level dependent (BOLD) measurements.2 Synchronized changes in neuronal activity across different regions of the brain can be viewed as functional neuroanatomical circuits coordinating the thoughts, memories, and emotions for particular behaviors. ...........